Healthcare Industry News: Halcyon
News Release - September 21, 2017
Varian Announces Penn Medicine Treats World's First Patient on Halcyon SystemPALO ALTO, Calif., Sept. 21, 2017 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems (NYSE: VAR) today announced a patient at Penn Medicine, with head & neck cancer, became the first person in the world to be treated on Varian's Halcyon™ system, its new platform for cancer treatment. Halcyon is well suited to handle the majority of cancer patients, offering advanced treatments for prostate, breast, head & neck, and many other forms of cancer.
The treatment for this patient at Penn Medicine was a complex case that involved the delivery of nine fields. The total patient time in the treatment room, including set-up, imaging, three minutes of beam time and patient discharge, was only 13 minutes*. Typically, a treatment like this using other radiation technology can take 10 minutes of beam time and 20 minutes total treatment time.
Halcyon is an advanced system that is more comfortable for the patient while delivering ease of use for healthcare providers, accelerated installation timeframes, expedited commissioning, simplified training, and automated treatment.
"The first patient treatment is a major milestone for the Halcyon system," said Kolleen Kennedy, president of Varian's Oncology Systems business. "Working closely with leading institutions like Penn Medicine, helped shape the human-centered design focus of Halcyon and our ability to deliver a system that simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). We are excited to see treatments commencing and continuing our efforts of advancing cost-effective cancer care worldwide."
"We are proud to have delivered the world's first Halcyon treatment, which contributes to our ongoing mission to provide patients the widest and most advanced array of cancer treatment options," said James Metz, MD, chair of Radiation Oncology at Penn Medicine. "This platform combines reduced treatment time with simplified operation, and for some diseases, it even lets us be more precise with the radiation we're delivering."
For more information on Halcyon, visit www.varian.com/Halcyon
About Varian Medical Systems
Varian Medical Systems focuses energy on saving lives and is the world's leading manufacturer of medical devices and software for treating and managing cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,600 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
*Results may vary
Source: Varian Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsThree Radiotherapy Centers in Serbia Standardize on Varian Solution for Cancer Treatment Planning
Varian to Expand Interventional Oncology Portfolio with Purchase of Embolic Bead Asset
Cyclotron for Varian ProBeam Compact Proton Therapy System Installed at New Treatment Center in Singapore